A phase IIa study of rhLTα-Da in combination with cisplatin and fluorouracil for patients with metastatic esophageal squamous cell carcinoma or gastric adenocarcinoma
Wang Feng-hua
Wang Yun
Chen Zhen-dong
Chen Jian-hua
Qin Feng-zhan
Jiang Wen-Qi
Li Yu-hong
· 2016
期刊名称：
Medical Oncology
2016 年
33 卷
11 期
摘要：
Recombinant human lymphotoxin-?± derivative (rhLT?±-Da) is a lymphotoxin-?± derivative missing 27??N-terminal amino acid residues. This multicenter phase IIa trial was conducted to evaluate the safety, efficacy and pharmacokinetics of rhLT?±-Da with cisplatin (DDP) and 5-fluorouracil (5-Fu) for metastatic esophageal squamous cell cancer (ESCC) and gastric adenocarcinoma (GC). Two different rhLT?±-Da doses (10????g/m
会员登录
